实时定量PCR检测miRNA-29a在肝癌中的变化

Expression of miRNA-29a in Hepatocellular Carcinoma

目的:探讨微小RNA(miRNA)-29a在正常人和原发性肝癌患者血清,以及原发性肝癌患者的正常肝脏组织和肝癌组织中的表达。方法:应用荧光实时定量PCR方法检测miRNA-29a,在正常人和原发性肝癌患者血清水平。同时收集并检测原发性肝癌患者术中取得的正常肝脏组织和癌症组织中miRNA-29a的含量。结果:1)与正常人血清相比,miRNA-29a在原发性肝癌患者血清中水平没有明显改变(P>0.05)。2)与正常肝脏组织相比,原发性肝癌患者肝癌组织中miRNA-125含量明显降低,有统计学差异(P<0.01)。结论:MiRNA-29a在原发性肝癌患者的肝癌组织中表达显著降低,但患者的血清水平并没有明显改变。

Objective： To investigate the expression of miRNA-29a in sera of the normal subjects and patients with primary liver cancer, and the expression of miRNA-29a in normal liver tissues and hepatocellular carcinoma tissues in patients. Methods： MiRNA-29a in sera of normal subjects and patients with primary liver cancer. At the same time, the normal liver tissues and hepatocellular carcinoma tissues of patients were collected and detected by using florescent real-time quantitative PCR. Results： 1） Compared with the normal subjects, the level of miRNA-29a had no obvious change in sera of patients with primary liver cancer （P〉0.05）. 2） Compared with the normal liver tissues, the level of miRNA-29a was markedly decreased in hepatocellular carcinoma tissues in the patients with primary liver cancer （P 〈0.01）. Conclusion： The expression of miRNA-29a in hepatocellular carcinoma tissues was decreased than in normal liver tissues of patients with primary liver cancer. But there was no obvious change in the sera of normal subjects and of patients.